KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Interest Expenses (2017 - 2025)

Historic Interest Expenses for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $2.8 million.

  • Aquestive Therapeutics' Interest Expenses fell 3.6% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 475.7%. This contributed to the annual value of $11.1 million for FY2024, which is 7550.89% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Interest Expenses stood at $2.8 million, which was down 3.6% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Interest Expenses peaked at $2.8 million during Q3 2021, and registered a low of $1.3 million during Q3 2023.
  • In the last 5 years, Aquestive Therapeutics' Interest Expenses had a median value of $2.8 million in 2021 and averaged $2.2 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Interest Expenses plummeted by 4139.8% in 2022, and later soared by 12133.76% in 2024.
  • Aquestive Therapeutics' Interest Expenses (Quarter) stood at $1.7 million in 2021, then dropped by 5.39% to $1.6 million in 2022, then surged by 37.76% to $2.3 million in 2023, then increased by 22.26% to $2.8 million in 2024, then changed by 0.0% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $2.8 million for Q2 2025, and $2.8 million during Q1 2025.